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Background: Amyotrophic lateral sclerosis (ALS) is characterized by selective degeneration of motor neurons. The
gene encoding Cu/Zn superoxide dismutase (SOD1) is responsible for 20% of familial ALS cases. Growth hormone
(GH) concentrations are low in the cerebrospinal fluid of patients with ALS; however, its association with motoneuronal
death is not known. We tested the neuroprotective effects of GH on human SOD-1-expressing cultured motor neurons
and SOD1G93A transgenic mice.
Results: In cultured motor neurons, cytotoxicity was induced by A23187, GNSO, or homocysteine, and the effects
of GH were determined by MTT, bax, PARP cleavage pattern, Hoechst nuclear staining, MAPK, and PI3K assay. In
SOD-1 transgenic mice, rotarod motor performance was evaluated. Survival analysis of motoneuronal loss was done
using cresyl violet, GFAP, and Bcl-2 staining. GH prevents motorneuronal death caused by GSNO and homocysteine,
but not that by A23187. It activates MAPK and PI3K. GH-treated mice showed prolonged survival with improved motor
performance and weight loss. GH decreased cresyl violet positive motoneuronal loss with strong Bcl-2 and less GFAP
immunoreactivity.
Conclusions: Our results demonstrate that GH has a protective effect on mutant SOD-1-expressing motor neurons.
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Amyotrophic lateral sclerosis (ALS) is a degenerative
disorder [1,2] characterized by selective degeneration of
motor neurons predominantly in the anterior horn of
the spinal cord and brainstem, and pyramidal cells of the
motor cortex. ALS leads to progressive weakness, atrophy
of skeletal muscles, and eventual paralysis and death,
usually within 2–5 years [3].
Up to 10% of ALS cases are familial (fALS); the
remaining 90% have no hereditary component and are
known as sporadic ALS [4]. About 20% of fALS cases
are caused by autosomal dominant mutations in the
gene encoding for Cu/Zn superoxide dismutase (SOD1)
[5]. Pathophysiological mechanisms of fALS due to
SOD1 mutations include a failure to fold or degrade
mutant SOD1, production of free radicals, release of free* Correspondence: kimmanho@snu.ac.kr
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unless otherwise stated.copper, or susceptibility of mutant SOD1 to disulfide
reduction [6-8].
Many studies have implicated oxidative stress and an
excitotoxic mechanism in the pathogenesis of ALS.
Plasma homocysteine (HC), which is continuously pro-
duced from diet and increases with age, has been consid-
ered to play a role in motor neuronal death, thus
resulting in ALS. HC in vascular systems produces react-
ive oxygen species (ROS), such as superoxide anions,
and reduces transitional metals by reaction of the metal
with molecular oxygen. NO (Nitric oxide) might be in-
volved in the mechanism of action of HC. NO is scav-
enged for transformation into peroxynitrite by reaction
with the superoxide anion generated by HC. This react-
ive peroxynitrite causes cell death by oxidative damage,
disruption of energy metabolism, calcium homeostasis,
and mitochondrial function [9,10]. In addition, motor
neurons in SOD1 models are vulnerable to excitotoxicity
by glutamate; glutamate receptor-mediated neurodegen-
eration is associated with calcium influx and substantial
intracellular calcium accumulation [11,12].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chung et al. BMC Neuroscience  (2015) 16:1 Page 2 of 11Growth hormone (GH), a high molecular weight pep-
tide composed of 191 amino acids, is produced by the
anterior lobe of the pituitary gland. GH functions either
by direct action on tissues or through the insulin-like
growth factor-1. It causes proliferation of many types of
cells and controls differentiation in adipose or muscle
tissues. It also controls the metabolism of proteins, car-
bohydrates, or fatty acids [13,14]. Although the effect of
GH on the central nervous system (CNS) was first
reported over 60 years ago, virtual data have appeared in
the past decade [15-17]. GH secretion was studied in
myotonic dystrophy. This condition was associated with
an abnormal pattern of GH secretion over 24 hours and
a significant decrease in its circulating levels [18,19].
One study reported a reduction of GH secretion in
patients with ALS [20].
In the present study, we examined the protective effect
of GH on motor neuronal death. We tested the effect of
GH on the viability of motoneuron-neuroblastoma
hybrid cells (VSC4.1) expressing mutated human SOD1
against cytotoxic stimuli. In addition, we attempted to
determine whether GH treatment has a neuroprotective
effect on transgenic mice with the SOD1G93A mutation.
Lifespan and body weight measurements, rotarod test,
and immunohistochemistry for motor neuronal loss were
performed.Figure 1 PI3-kinase or MAP-kinase inhibitor treatment and activation
W13 (p = 0.039) (A). Increased viability of G93A was reduced by treatment
at 0.004 I.U/ml and active pAkt and pERK forms were identified 5, 10, and 2
cell lines at different time points were analyzed (C). Results are expressed aResults
The effect of GH on mutant human SOD1 cell lines
Cell lines were cultured with various GH concentrations
for 24 h (0.0004 I.U./ml to 0.4 I.U./ml). The number of
living cells increased in the A4V cell line (p = 0.015) and
G93A cell line (p = 0.034) as determined by the MTT
assay. However, there was no statistical difference with
the number of viable cells in the WT cell line.
When treated with W13 (P13K inhibitor), the increasing
viability of A4V with pretreated GH decreased (p = 0.039)
(Figure 1A). However, it was not significantly different
from the WT and G93A cell lines. When treated with
P098050 (MAPK inhibitor), the increasing viability of
G93A with pretreated GH decreased (p = 0.038) (Figure 1B).
However, the difference was not significant from that of
the WT and A4V cell lines. For immunoblotting studies,
A4V and G93A cell lines were treated with GH (0.004 I.
U./ml) and active pAkt and pERK forms were identified.
The change of pAkt in A4V cell line (p = 0.022) and
G93A cell line (p = 0.034) at different time points had
statistical significance. Similarly, pERK levels also
changed significantly in A4V (p = 0.038) and G93A cell
lines (p = 0.019) at different time points. In A4V cells,
the ratio of pAkt and pERK were higher than those in
G93A but the difference was not significant (p = 0.05)
(Figure 1C).of pAkt and pERK by GH. Increased viability of A4V was reduced by
with PD098059, a MAP-kinase inhibitor (p = 0.038) (B). GH was applied
0 min later. The change in levels of pAkt and pERK in A4V and G93A
s mean values and SD (*p < 0.05).
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In previous studies, treatment with A23187, calcium in-
flux, GSNO, NO-donor, and homocysteine had a select-
ive cytotoxic effect in the mutated SOD-1 cell lines,
G93A, and A4V. Viabilities of G93A and A4V decreased
compared to that of WT [9,21]. In this study, these ef-
fects were reconfirmed.
Lack of the protective effect of GH on cytotoxicity of
A23187
When treated with A23187 (5 μM), cell viabilities decreased
but did not reach significance. Viabilities in A4V and G93A
decreased by 10% and 20%, respectively, which was
higher than that in WT. Pretreatment with 0.04 I.U./ml
and 0.4 I.U./ml GH had no protective effect on WT,
A4V, and G93A cell lines.
The protective effect of GH on the cytotoxicity of GSNO
GSNO (200 μM) treatment caused a non-significant
reduction in viabilities. The reduction was 20% in A4V
and 10% in G93A, and was higher than in WT. Pretreat-
ment with 0.04 I.U./ml and 0.4 I.U./ml GH caused via-
bilities in WT and A4V to increase, but not significantly
(Figure 2A). Nuclear fragmentation was observed after
GSNO (200 μM) treatment which decreased by pretreat-
ment with 0.4 I.U./ml GH, but there were no statistically
significant difference (Figure 2C). While there were no
changes in Bax expression, PARP expression (24 kDa,
116 kDa) increased after treatment with GSNO 200 μM,
but protective effect of GH was not observed in A4V
and G93A cell lines (Figure 2D).
The protective effect of GH on the cytotoxic effect with
Homocysteine
When treated with homocysteine (10 μM), cell viabilities
decreased but was not significantly different compared
to WT. Viabilities in A4V and G93A decreased more
than that in WT (by 20% and 40%, respectively). The
protective effect of GH was observed in A4V, especially
at 0.4 I.U./ml (p = 0.046) (Figure 2B). Homocysteine also
caused nuclear fragmentation which decreased by pretreat-
ment with 0.4 I.U./ml GH (p = 0.039) (Figure 2C); however,
there were no changes in Bax and PARP expression.
GH improves motor performance
To investigate improvements in balance and coordination,
we used the rotarod test. GH treatment significantly im-
proved motor performance at 16 weeks, compared to
saline-treated SOD1G93A mice (P = 0.017) (Figure 3A).
GH improves weight loss
In order to examine weight loss, we monitored mouse
body weights weekly. Mice in both groups were weighed
from 11 weeks of age. GH treatment significantly improvedweight loss at 18 weeks (p = 0.004) and 19 weeks
(p = 0.040) (Figure 3B).
GH improves lifespan
To determine the protective effects of GH on lifespan,
GH was injected weekly from postnatal 11 weeks till
death (5.583 μg/kg, i.p.) in GH-treated SOD1G93A
transgenic mice. After treatment, lifespan was compared
with saline-treated SOD1G93A transgenic mice. GH-
injection resulted in a significant improvement in
lifespan (P = 0.019) (Figure 3C). Mean mouse survival
increased from 132 ± 9 days to 143 ± 8 days.
Immunoreactivity analysis of the effect of GH on motor
neuron loss
In GH-treated SOD1G93A transgenic mice, there was a
reduction in the number of cresyl violet-positive neu-
rons, compared to non-transgenic mice, but a significant
increase was noted compared to that in saline-treated
SOD1G93A transgenic mice (p = 0.027) (Figure 4A, D).
To determine whether GH exerted a neuroprotective ef-
fect in SOD1G93A transgenic mice, we examined GFAP
expression in astrocytes by immunohistochemistry. Lumbar
spinal cord sections of saline-treated SOD1G93A trans-
genic mice showed strong GFAP immunoreactivity. In
contrast, the GFAP signal was attenuated in the lumbar
spinal cord of GH-treated SOD1G93A mice and non-
transgenic mice (Figure 4B). Next, we performed immu-
nostaining for Bcl-2 in order to determine if GH inhibits
apoptotic neuronal death in SOD1G93A transgenic mice,
(Figure 4C) and found stronger immunoreactivity com-
pared to saline-treated SOD1G93A mice.
Discussion
A few studies on halting disease progression in SOD1-
dependent ALS have been carried out. The effect of GH
on the CNS appears to involve brain growth and devel-
opment, and action as a neuroprotective factor [15-17].
We tested the neuroprotective effects of GH on human
SOD-1-expressing cultured motor neurons and SOD1G93A
transgenic mice. The results showed that GH protects
against motorneuronal death caused by GSNO and homo-
cysteine, but not by A23187. GH activated MAPK and
PI3K. Prolongation of survival was observed in GH-
treated mice, along with improved motor performance
and weight loss. GH decreased cresyl violet positive
motoneuronal loss with stronger Bcl-2 and lesser GFAP
immunoreactivity. Our results suggest that GH has a
protective effect on mutant SOD-1 expressing motor
neuronal death.
Zhang et al. [21] demonstrated that folic acid protects
motor neurons against increased homocysteine, inflam-
mation, and apoptosis in SOD1G94A transgenic mice.
Folic acid, which was applied to SOD1G94A transgenic
Figure 2 Cytoprotective effect of GH. The protective effect of GH with GSNO pretreatment was observed in mutant cells (A). In homocysteine-treated
cells, reduced viabilities in A4V were partly reversed by GH at 0.4 I.U/ml (p = 0.046) (B). GSNO treatment increased nuclear fragmentation; GH treatment
reduced this phenomenon. Homocysteine also reduced cell viability and the number of fragmented nuclei; this was reversed by pretreatment with GH
(p = 0.039) (C). GSNO treatment increased 116 kD and 24 kD PARP fragments in A4V and G93A cells, which were reduced by GH treatment (D). Results
are expressed as mean values and SD (*p < 0.05).
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metabolism. The study showed that folic acid treatment
significantly delayed disease onset and prolonged lifespan,accompanied by significantly attenuated plasma homo-
cysteine levels, suppressed activation of microglia and
astrocytes, and inhibited expression of inducible nitric
Figure 3 (See legend on next page.)
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Figure 3 In vivo study. In the rotarod test, GH treatment significantly improved motor performance at 16 weeks, compared to saline-treated
SOD1G93A mice (p = 0.017) (A). GH treatment significantly improved weight loss at 18 (p = 0.004) and 19 weeks (p = 0.040) (B). GH treatment
resulted in a significant improvement in lifespan, compared with saline-treated SOD1G93A transgenic mice (p = 0.019) (C). Y error bars represent
standard error of the mean (±SD) (*p < 0.05).
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in the spinal cord. Pyruvate has been known as an anti-
oxidant and an energy source. When pyruvate was ap-
plied in SOD1G94A transgenic mice, lifespan increased,
disease progression slowed, and motor performance
improved. However, disease onset was not observed to
be delayed in this study [22].
GH levels decrease after peaking during adolescence;
one third of people over 65 years of age are deficient in
GH. Therefore, GH replacement therapy is used as one
of the clinical practices for reducing the aging
phenomenon [23]. Despite the direct application of GH
in slowing aging, the mechanism underlying cytoprotec-
tion afforded by GH remains unknown. Only a few stud-
ies have shown that GH administration prevents organ
and tissue deterioration due to aging. As a possible
mechanism of its action, GH has been suggested to act
on antioxidant enzymes in the modulation of regulatory
pathways in reduction of ROS generation. Moreover, GH
has been shown to prevent age-induced reduction in
expression of some components, including cytochrome
b and c of the mitochondrial respiratory chain [24,25].
Therefore, we hypothesized that GH has a cytoprotective
effect associated with mitochondria in the SOD-1 mu-
tant. Studies on the CNS have shown that GH has a
neuroprotective effect against ischemic brain injury, can
attenuate trauma-induced depression of spinal cord
evoked potentials, and can ameliorate motor dysfunction
resulting from spinal cord injury [26-28]. CNS weight
increases in overexpression of GH and so does the size
of lumbar spinal motor neurons. However, there is no
relative evidence to demonstrate a lack of alteration in
motoneuron numbers in the CNS of GH receptor-
deficient mice. Some studies have shown that GH,
Insulin-like Growth Factor-1, and insulin concentrations
in cerebrospinal fluid (CSF) are significantly lower in pa-
tients with ALS in comparison with the control group
[29-33]. However, it is unknown whether GH affects the
survival of motor neurons in ALS. Morselli et al. [20]
suggested that two-thirds of patients with ALS present
with growth hormone (GH) deficiency. Based on this
data, several clinical trials were performed with GH on
patients with ALS [34,35]. However these studies failed
to show any significant impact on motor symptoms or
patient survival, except in a few patients who seemed
to be good GH-responders. Therefore, more studies
are needed to investigate the effect of GH on motor
neurons.In our study, GH was protective against GSNO and
homocysteine in mutant SOD-1-expressing cells [9,36,37].
However, this effect was not observed in cells treated
with A23187, suggesting that GH is not related to
calcium-influx-mediated cell death. Additionally, the
protective effect of GH appears to be related to nuclear
fragmentation and not the Bax protein, an indicator of
mitochondria-related cell death. PARP cleavage and cas-
pase 3 represent the signals of apoptosis, which are
related to mitochondria-related cell death. Reactive as-
trocytes in the CNS of SOD1G93A transgenic mice have
been shown to express cleaved PARP [21,38-40]. With
GSNO treatment, GH decreases PARP cleavage, sug-
gesting that GH may affect caspase 3. However, with
homocysteine treatment, GH does not affect PARP
cleavage, suggesting that it is not related to caspase 3.
Therefore, the protective effect of GH in our study may
be attributed to a non-mitochondrial mediated apop-
tosis, i.e., another non-developmental pathway.
In case of Figure 1A, we showed the proliferating
effect of GH on A4V that is blocked by W13. However,
in Figure 2A, we attempted the NO cytotoxicity and
checked whether this cytotoxicity can be protected by
GH. We assumed that Figure 1A could show the signifi-
cant difference the viability of A4V cells because W13 is
directly related with the GH receptor cascade. Figure 2A
showed the tendency of increasing viability of A4V cells.
The main signaling pathway of GH is through the GH
receptor related to the tyrosine kinase Janus tyrosine
kinase-2 (JAK2). JAK2 is activated when a GH molecule
binds to a dimer of the GH receptor and JAK2, which
promotes the phosphorylation of both JAK2 and the GH
receptor. Subsequently, STAT 1, 3, and 5 dimerize and
translocate to the nucleus in order to activate transcrip-
tion of the target gene. JAK2 also phosphorylates and
potentiates the mitogen-activated protein kinase (MAP
kinase) and phosphatidyl inositol-3 kinase (PI3 kinase)
cascades to proliferate survival related cells [41]. The
proliferative effect of GH was observed at concentrations
between 0.0004–0.004 I.U., which was negated by the
inhibitors of PI3 kinase or MAP kinase, suggesting that
this proliferation is mediated by survival signaling. The
effect of PI3K or MAPK appeared to differ among the
cell lines. The PI3 kinase inhibitor mainly affected A4V,
but not WT and G93A. However, the MAP kinase in-
hibitor mainly affected G93A, and not WT and A4V.
pAkt levels suggested that PI3K signaling [42] is acti-
vated in A4V and G93A cell lines. Increased pERK levels
Figure 4 (See legend on next page.)
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Figure 4 Histopathological analysis by cresyl violet, GFAP, and Bcl-2 staining. Cresyl violet staining revealed few numbers of neurons in
saline-treated SOD1G93A mice, and higher numbers in non-transgenic and GH-treated SOD1G93A mice (A). GFAP immunoreactivity was observed
at very low levels in non-transgenic mice, and at significantly higher levels in saline-treated SOD1G93A mice (B). Increasing GFAP immunoreactivities
in saline-treated SOD1G93A mice were attenuated by GH treatment. Bcl-2 staining (C) is stronger in GH-treated SOD1G93A mice than in saline-treated
SOD1G93A mice. (×200) The number of motor neurons is significantly higher in the non-transgenic and GH-treated SOD1G93A mice (p = 0.027)
(D). Results are expressed as mean values and SD (*p < 0.05).
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active in A4V and G93A cell lines.
It would be ideal to use mice of the same sex to avoid
possible gender differences. Unintentionally, random
assignment results in different sex ratio. However, no
behavioral or phenotypic gender difference related to
G93A mutation was found in G53A C57BL/6 J trans-
genic mice [43]. A significant reduction in astrogliosis,
as assessed by glial fibrillary acidic protein (GFAP) stain-
ing was observed, which suggests delayed astrocyte acti-
vation in GH-treated SOD1G93A transgenic mice.
Reduced expression of Bcl-2 has been observed in the
spinal cord of transgenic mice expressing SOD1 with the
G93A mutation [44] and in human patients having ALS
without SOD1 mutations [45]. Bcl-2 is an important
inhibitor of most types of apoptotic cell death, and may
reduce motor neuron losses by obstructing the activa-
tion of apoptosis induced by Cu/Zn-SOD mutation [7].
In addition, it has been demonstrated that Bcl-2 expres-
sion is reduced in symptomatic SOD1G93A transgenic
mice [44].
Conclusion
Our results demonstrate that GH has a protective effect
in mutant SOD-1-expressing motor neuronal death. We
confirmed these results with in vitro and in vivo studies
in mutant SOD1 cells and mice, respectively. Our results
further indicate that the protection afforded by GH to
mutant SOD-1 expressing motor neurons could be
through a novel non-mitochondrial mediated pathway
that is different from the established pathway. However,
more trials are needed in order to further clarify the
neuroprotective mechanism of GH action.
Methods
Cell culture
Motoneuron-neuroblastoma hybrid cells (ventral spinal
cord 4.1 [VSC 4.1]; a generous gift from Dr. SH Appel,
Baylor College of Medicine, USA) [14,46], which are a
fusion product between neuroblastoma N18TG cells and
dissociated embryonic rat ventral spinal cord, were main-
tained in Dulbecco’s modified Eagles’ medium/F-12 growth
medium (Gibco, Grand Island, NY) with Sato’s compo-
nents (Sigma, St. Louis, MD) and 2% heat-inactivated new-
born calf serum (HyClone, Logan, UT). This cell line
has certain similarities with mammalian motoneuronssuch as dibutyryl cAMP- or 8-bromocAMP-inducible
choline acetyltransferase, neuron-specific enolase, immu-
noreactive 200-kDa neurofilament protein, synaptophysin,
active voltage-gated calcium channels, and expression of
calcium binding proteins (calbindin-D28K and parvalbu-
min) modulated during differentiation [14,47]. They were
grown in log-phase on poly-(L-ornithine)-precoated cul-
ture dishes (Falcon, Franklin lakes, NJ) [48,49]. Cells were
plated in 96-well plates at a density of 1 × 104 cells per
well. For the immunoblotting and SOD activity assay,
some cells were seeded in 100 mm dishes at 1 × 105 cells.Constructs and establishment of stable cell line
Human SOD-1 cDNA from normal and mutant cells
was cloned into the BamH1 and EchoRI1 sites of
pcDNA 3.0 (Invitrogen, Carlsbad, CA). Cells were des-
ignated as wild-type, A4V (mutant cells having SOD1
with alanine substituted to valine at position 4), and
G93A (mutant cells having SOD1 with glycine substituted
to alanine at position 93). These constructs were a gift from
Dr. Lawrence J. Hay-ward (University of Massachusetts,
Boston, USA) [14,46]. Following transfection (Superfect,
Qiagen, Valencia, CA), the cells were maintained in a
medium that contained G418 at a concentration of
400 μg/ml (Gibco, Grand Island, NY). Single or pooled
colonies were used for the experiment after confirming
expression of human SOD1 (WT, A4V, G93A) by
Western blot analysis using an anti-human SOD1 poly-
clonal antibody (Calbiochem, La Jolla, CA). These cell
lines were grown and differentiated under the same
conditions as those of VSC 4.1 cells [48].Growth hormone application
Growtrophin 4 I.U./vial (Donga pharmaceutical, Korea)
is a highly purified human growth hormone (hGH)
produced by the E.coli strain K-12 (W3110) which
overexpresses the hGH expression vector (pHGH401).
The hGH gene is modified to remove a methionyl
group. Its physiological potency is equivalent to that of
the pituitary-derived hGH. Growtrophin 4 I.U. (1.34 mg)/vial
was used and reconstructed with 1 ml distilled water.
For the experiment, reconstructed Growtrophin was
diluted with culture media. The concentration started
from 0.0004 I.U./ml (0.134 μg/ml) to 4.0 I.U./ml
(1.34 mg/ml) [14].
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The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltertazolium
bromide (MTT) assay was used for determination of cell
viability. In brief, MTT solution (5 mg/ml in PBS) was
added to cultures. Following a 3-h incubation period,
the MTT solution was removed and formazan precipi-
tate was dissolved in 200 μl dimethyl sulfoxide (DMSO).
Hoechst nuclear staining
For staining, cells were plated on coverslips coated with
poly-D-lysine (10 μg/ml; Sigma, St. Louis, MD) and were
fixed with 4% paraformaldehyde for 20 min. Hoechst 33,
342 dye (molecular probe, Eugene, OR) was diluted at 1:
1000 with phosphate buffered saline (PBS) and incu-
bated for 5 min at room temperature. Morphological
changes in the nuclei were observed using a fluorescence
microscope. To determine any evidence of apoptosis,
nuclear fragmentation or chromatin condensation were
examined [50].
Cytotoxic stimuli
In order to induce cytotoxicity by production of reactive
oxygen species (ROS), we used homocysteine and S-
nitrosoglutathione (GSNO), a nitric oxide donor, which
have been previously reported. For calcium induced
cytotoxicity, the ionophore A23187 was used for calcium-
influx. The concentrations were used as previously de-
scribed: GSNO 200 μM, homocysteine 10 mM, A23187
5 μM [9,36]. We evaluated cell viability or cytotoxicity by
the MTT assay and Hoechst nuclear staining. Cell viability
between WT and mutated SOD1-expressing cells was
compared to test the protective effect of GH in mutant
SOD1 cells; cells were preincubated with GH for 30 min
before the cytotoxic stimuli.
PI3K (Phosphatidylinositol 3-kinase) and MAPK (Mitogen
Activated Protein Kinase) assay
PI3K and MAPK were inhibited using wortmannin (W13:
Sigma, St. Louis, MO), and 10 μM P098050 (Sigma, St.
Louis, MO), respectively. Phosphorylated Akt (pAkt) was
assayed for PI3K activation and phosphorylated ERK
(pERK) for MAPK activation.
Protein extraction and Western blot analysis
Total proteins were extracted with RIPA buffer, to which
protease inhibitors (complete Mini, GIBCO, Grand Island,
NY) had been freshly added. Protein concentration was
determined by the Bradford method (Bio-Rad, Richmond,
CA). Protein extracts (20 μg) were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. Pro-
tein separation was performed in 10% polyacrylamide
with 0.05% bis-acrylamide and transferred to a nitro-
cellulose membrane. Anti-PARP (1:1000 dilution; Cell
Signaling Technology, Berverly, MA), anti-Bax (1:1000dilution; Santa Cruz Biotechnology, Santa Cruz, CA),
anti-pAkt (1:1000 dilution; Cell Signaling Technology,
Berverly, MA), and anti-pERK (1:1000 dilution; Cell Sig-
naling Technology, Berverly, MA) were used as primary
antibodies. Anti-tubulin antibody (1:2000 dilution; NeoMar-
kers) was used for standardization of the protein amount.
Immunoreactivity was detected by enhanced chemilumin-
escence (Supersignal, Thermo Scientific, Rockford, IL).
Animal model
Transgenic TgN (SOD1G93A) 1GUR mice were ob-
tained from the Jackson Laboratory (Bar Harbor, ME).
These mice express high-copy numbers of the transgenic
human mutant SOD1 containing the Gly 93 to Ala
(G93A) substitution [51]. SOD1G93A transgenic mice
were bred with B6SJLF1/J hybrid females. The presence
of the human G93A transgene was confirmed by PCR
assays of DNA in the tail tissue of transgenic offspring.
Sixteen SOD1G93A transgenic mice and four wild (non-
transgenic) mice were used for this experiment. All mice
were housed under a 12-h light/dark cycle. All animal
studies were carried out with the approval of the Institu-
tional Animal Care and Use Committee (IACUC) of Seoul
National University Hospital, which was accredited by the
Association for the Assessment and Accreditation of
Laboratory Animal Care International. Transgenic
littermates were randomly assigned to a control (saline-
treated) or GH-treated group. Intraperitoneal (i.p.) injec-
tions of 1.6749 μg (5 I.U.)/30 g GH (n = 9; 1 male and 8
females) or saline only (n = 7; 6 males and 1 female)
were administrated weekly from postnatal week 11 to
death. Body weight was recorded once a week until the
mice were able to perform the behavioral task [22].
In ALS model mice, shaking of the limbs and suspen-
sion of the tail in the air are the initial symptoms of
disease onset. At this stage, clonus, hyperreflexia, and
crossed spread of spinal reflexes are also detectable in
most mice. Subsequently, these mice develop gait im-
pairments and paralysis of one (or both) hind limbs; in
the final stage these mice are completely paralyzed. The
end point was noted when ALS model mice could not
right themselves within 30 s when placed on their sides
on a flat surface; at this point they were sacrificed by
cervical dislocation [52,53].
Rotarod test
Using a previously described protocol, the Rotarod (Ugo
Basile, Comerio, Italy) test was used in SOD1G93A mice
from 11 weeks of age [54]. Training was performed from
10 weeks of age over 3 consecutive days, and testing
began by placing mice individually on a rod (diameter =
4 cm), rotating at a constant speed of 16 rpm. Time
taken before mice fell off the rod (3 min maximum) was
recorded, and used a measure of motor function. During
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gest duration spent on the rod was recorded. Mice were
tested once a week until they were able to perform the
task [22].
Immunohistochemistry
For immunohistochemistry, mice were deeply anesthe-
tized and perfused transcardially with cold 0.1 M PBS,
followed by cold 4% paraformaldehyde for 10 min.
Spinal cords were carefully dissected to obtain 4–10 mm
long segments. Lumbar and cervical cords were identi-
fied by enlargement of the spinal cord. Tissues were
postfixed in 4% paraformaldehyde for 8 h, and the tissue
blocks produced were cryoprotected in a series of cold
sucrose solutions of increasing concentration for 24 h.
Transverse sections (30-μm thicknesses) were taken
through lumbar and cervical cords. Cresyl violet acetate
(Sigma, MO) staining was performed using these sec-
tions and incubated using the free-floating method
(24–72 h, 4°C) with one of the following primary anti-
bodies: monoclonal anti-glial fibrillary acidic protein,
GFAP (1:500 dilutions; Sigma); or Bcl-2 (1:500 dilution;
Santa Cruz Biotech, CA).
Data analysis
The samples were analyzed in triplicate. For in vitro
studies, values were expressed as mean ± SD, inter-group
analysis by treatment was performed using Kruskal-
Wallis or Mann-Whitney tests. Dose-dependent decrease
in viability was determined using LD50. For in vivo stud-
ies, values are expressed as mean ± SD. Kaplan-Meier
survival analysis and the Log-rank test were used for
comparisons of survival. Body weight and rotarod test
analysis by treatment were performed using the Mann-
Whitney test. Statistical significance was accepted
when p-value was less than 0.05. SPSS10.0 (SPSS Inc.,
Chicago, IL) program was used for statistical analysis.
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